Validation of the all-comers design: Results of the TARGET-AC substudy
- 27 November 2019
- journal article
- research article
- Published by Elsevier BV in American Heart Journal
- Vol. 221, 148-154
- https://doi.org/10.1016/j.ahj.2019.10.019
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trialThe Lancet, 2019
- Safety and efficacy of the COMBO bio-engineered stent in an all-comer PCI cohort: 1-Year final clinical outcomes from the MASCOT post-marketing registryInternational Journal of Cardiology, 2019
- Intravascular Ultrasound Versus Angiography-Guided Drug-Eluting Stent Implantation The ULTIMATE TrialJournal of the American College of Cardiology, 2018
- Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trialThe Lancet, 2018
- Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trialThe Lancet, 2018
- Letter: Enrollment-To-Screening Ratio: An Undervalued Data in Randomized Clinical TrialsNeurosurgery, 2018
- Evaluating the 'all-comers' design: a comparison of participants in two 'all-comers' PCI trials with non-participantsEuropean Heart Journal, 2011
- Patients enrolled in coronary intervention trials are not representative of patients in clinical practice: results from the Euro Heart Survey on Coronary RevascularizationEuropean Heart Journal, 2006
- Is the Randomized Clinical Trial the Gold Standard of Research?Journal of Andrology, 2001
- Understanding controlled trials: Why are randomised controlled trials important?BMJ, 1998